Vanda Pharmaceuticals Reports Second Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Vanda Pharmaceuticals (VNDA) Tops Q2 EPS by 31c
August 2, 2017 4:21 PM EDTVanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 EPS of $0.03, $0.31 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $42.06 million versus the consensus estimate of $40.31 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
... More